Technical Data
SAPK2, p38 MAPK Inhibitor (SB 202190) (Stress-activated Protein Kinase 2)
Molecular Biology Storage: -20CShipping: Blue Ice
SB 202190 is a cell permeable pyridinyl imidazole, which acts as a strong inhibitor of SAPK2a/p38 and SAPK2b/p38beta MAP kinases (IC50=280nM and 350nM, respectively). SB 202190 has no effect on the activity of the Erk or SAPK/JNK MAP kinases and is reported to block LPS induced TNF-a and IL-1beta production in mice. The compound is a slightly better inhibitor than the related compound SB 203580.

Soluble in DMSO (50mg/ml).

Specific inhibitor of p38/SAPK2a MAPK and P38b/SAPK2a MAPK activity. Other applications not tested.

Protein Kinase Inhibition Assay:
When pre-incubated for five minutes with 0.2ug of SAPK2a/p38 MAPK or SAPK2b/p38beta MAPK, 1-10uM of SB 202190 will inhibit the activity of these kinases 80-95%. The final concentration of SB 202190 needed may depend on the amount of enzyme used. Optimal dilutions to be determined by the researcher.

Storage and Stability:
Stable for at least 12 months at -20C in the dark. After reconstitution, aliquot and freeze at -20C, away from light.

CAS Number:

Molecular Formula:

Molecular Weight:
Purity: 98% (HPLC)
Form: Supplied as a pale yellow solid.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Jiang, Y., et al., J. Biol. Chem. 271: 17,920 (1996). 2. Kramer, R.M., et al., J. Biol. Chem. 271: 27,723 (1996). 3. Li, Z., et al., Biochem. Biophys. Res Commun. 228: 334 (1996). 4. Lee, J.C., et al., Nature 372: 739 (1994).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.